A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study
Authors:
Open Access
- 3 June 2020
- journal article
- research article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 10 (6) , 1-11
Abstract
Targeted next-generation sequencing (tNGS) and ex vivo drug sensitivity/resistance profiling (DSRP) have laid foundations defining the functional genomic landscape of acute myeloid leukemia (AML) and premises of personalized medicine to guide treatment options for patients with aggressive and/or chemorefractory hematological malignancies. Here, we have assessed the feasibility of a tailored treatment strategy (TTS) guided by systematic parallel ex vivo DSRP and tNGS for patients with relapsed/refractory AML (number NCT02619071). A TTS issued by an institutional personalized committee could be achieved for 47/55 included patients (85%), 5 based on tNGS only, 6 on DSRP only, while 36 could be proposed on the basis of both, yielding more options and a better rationale. The TSS was available in <21 days for 28 patients (58.3%). On average, 3 to 4 potentially active drugs were selected per patient with only five patient samples being resistant to the entire drug panel. Seventeen patients received a TTS-guided treatment, resulting in four complete remissions, one partial remission, and five decreased peripheral blast counts. Our results show that chemogenomic combining tNGS with DSRP to determine a TTS is a promising approach to propose patient-specific treatment options within 21 days.Keywords
This publication has 37 references indexed in Scilit:
- A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain MetastasesCancers, 2019
- Functional genomic landscape of acute myeloid leukaemiaNature, 2018
- From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boardsGenome Medicine, 2018
- Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing AgentMolecular Cell, 2017
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark AnalysesClinical Cancer Research, 2014
- Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapiesScientific Reports, 2014
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory CancersJournal of Clinical Oncology, 2010
- Improved Statistical Methods for Hit Selection in High-Throughput ScreeningSLAS Discovery, 2003
- Complete Molecular Remission in Chronic Myelogenous Leukemia after Imatinib TherapyNew England Journal of Medicine, 2002